首页|Network Pharmacology of Xian-Lian-Jie-Du Decoction in Ameliorating Colorectal Cancer

Network Pharmacology of Xian-Lian-Jie-Du Decoction in Ameliorating Colorectal Cancer

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Objective:In this study,we screened for therapeutic targets of the Xian-Lian-Jie-Du decoction(XLJDD)for colorectal cancer(CRC)and explored the underlying mechanisms using network pharmacology techniques.Methods:Genes associated with CRC were collected from the GeneCards database.The names of the active compounds of XLJDD were used as keywords in the"chemical name"in the Traditional Chinese Medicine Systems Pharmacology(TCMSP)database to search the targets.The protein-protein interaction(PPI)network was constructed using Cytoscape 3.8.1.Gene Ontology functional enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analyses were performed to identify key target proteins.Results:A total of 234 XLJDD-related targets and 250 cross-targets between XLJDD and CRC were collected based on the TCMSP and HIT 2.0 databases.A PPI network constructed based on the STRING database revealed interactions for all 250 proteins.The network results revealed TP53,MYC,CCND1,AKT1,CASP3,and STAT3 as core potential targets.KEGG pathway analysis of the 250 potential XLJDD targets for CRC in the Metascape database was performed using RStudio software.The top 12 gene ratio aggregated analysis results were visualized in bubble charts.The interleukin(IL)-17 signaling pathway had the highest correlation with the tumor necrosis factor(TNF)signaling pathway.Conclusions:XLJDD may be effective in ameliorating CRC by controlling inflammatory factors related to the IL-17 and TNF pathways and targeting proto-oncogenes and tumor suppressor genes,including MYC,CCND1,CTNNB1,and TP53.

Colorectal cancernetwork pharmacologyXian-Lian-Jie-Du decoction

Ming-Xia Zhao、Cheng-Lin Song、Qin-Chang Zhang、Hao-Jie Du、Shu-Qiong Zhang、Yu-Xian Shen、Yang Sun、Hai-Bo Cheng、Wen Lv

展开 >

Department of Pharmacy,School of Basic Medical Sciences,Anhui Medical University,Hefei,Anhui,China

Department of Biopharmaceutical Research Institute,Anhui Medical University,Hefei,Anhui,China

Department of Pharmaceutical Analysis,State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing,China

Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor,First Clinical College,Nanjing University of Chinese Medicine,Nanjing,Jiangsu,China

Deparment of Biotechnology and Pharmaceutical Sciences,State Key Laboratory of Pharmaceutical Biotechnology,School of Life Sciences,Nanjing University,Nanjing,Jiangsu,China

Deparment of Gynecology,Institute of Traditional Chinese Medicine of Zhejiang Province,Tongde Hospital of Zhejiang Province,Hangzhou,Zhejiang,China

展开 >

National Key R&D Program of ChinaInnovation Team and Talents Cultivation Program of National Administration of TCMNational Science Foundation of ChinaNational Science Foundation of Zhejiang ProvinceClinical Research and Application Project of Zhejiang Health Science and Technology Plan

2022ZZ007ZYYCXTD-C-20220881930117LGF22H0400162022KY125

2024

10.4103/2311-8571.382074

世界中医药杂志(英文版)
世界中医药学会联合会

世界中医药杂志(英文版)

CSTPCD
ISSN：2311-8571
年,卷(期)：2024.10(1)
  • 50